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Yeast ubiquinone or coenzyme Q6 (Q6) is a redox
active lipid that plays a crucial role in the mitochon-
drial electron transport chain. At least nine proteins
(Coq1p–9p) participate in Q6 biosynthesis from 4-hy-
droxybenzoate (4-HB). We now show that the mito-
chondrial ferredoxin Yah1p and the ferredoxin reduc-
tase Arh1p are required for Q6 biosynthesis, probably
for the first hydroxylation of the pathway. Conditional
Gal-YAH1 and Gal-ARH1 mutants accumulate
3-hexaprenyl-4-hydroxyphenol and 3-hexaprenyl-4-
aminophenol. Para-aminobenzoic acid (pABA) is
shown to be the precursor of 3-hexaprenyl-4-amino-
phenol and to compete with 4-HB for the prenylation
reaction catalyzed by Coq2p. Yeast cells convert
U-(13C)-pABA into 13C ring-labeled Q6, a result that
identifies pABA as a new precursor of Q6 and implies
an additional NH2-to-OH conversion in Q6 biosyn-
thesis. Our study identifies pABA, Yah1p, and
Arh1p as three actors in Q6 biosynthesis.
INTRODUCTION
Coenzyme Q (ubiquinone or Q) is a lipophilic organic molecule
composed of a substituted benzoquinone and a polyprenyl chain
containing six units in Saccharomyces cerevisiae (Q6) and 10
units in humans (Q10). Q has a well-known role as an electron
carrier in the mitochondrial respiratory chain and also functions
as a membrane-soluble antioxidant (Bentinger et al., 2007).
Moreover, Q has been implicated in modulating the permeability
of transition pores (Fontaine and Bernardi, 1999) and is an oblig-
atory cofactor for the proton transport function of uncoupling
proteins (Echtay et al., 2001).
4-hydroxybenzoate (4-HB) is the long-known aromatic pre-
cursor of the benzoquinone ring of Q (Olson et al., 1963; Rudney
and Parson, 1963). Cells synthesize Q from 4-HB and fromChemistry & Biology 17,dimethylallyl diphosphate and isoprenyl diphosphate, the build-
ing blocks for the polyprenyl chain. After covalent linkage of the
polyprenyl tail to 4-HB to form 3-polyprenyl-4-hydroxybenzoate,
a total of one decarboxylation, three hydroxylation, and three
methylation reactions at the aromatic ring are necessary to yield
Q (Figure 1). Current knowledge of the genes involved in Q
biosynthesis in eukaryotes is mostly derived from the work per-
formed on yeast by Tran and Clarke (2007). So far, nine genes
(COQ1-9) have been characterized as essential for Q biosyn-
thesis in yeast, but only six gene products have been assigned
a catalytic role (Figure 1) (Kawamukai, 2009). All S. cerevisiae
COQ1-9 genes have human relatives. Primary Q10 deficiency,
a rare recessive disorder, has now been linked to mutations in
five genes: PDSS1 (Mollet et al., 2007) and PDSS2 (Lopez
et al., 2006; Mollet et al., 2007), which are the relatives of
COQ1; COQ2 (Mollet et al., 2007); COQ9 (Duncan et al., 2009);
and ADCK3/CABC1, the relative of COQ8 (Lagier-Tourenne
et al., 2008; Mollet et al., 2008).
Genetic and biochemical data have shown that a multiprotein
Q biosynthetic complex forms in yeast and associates with the
mitochondrial inner membrane on the matrix side (Tran and
Clarke, 2007). The proteins Coq3, Coq4, Coq6, Coq7, and
Coq9 are part of the Q biosynthetic complex (Tran and Clarke,
2007), and steady-state levels of these proteins are strongly
decreased in any coq null mutants that lack one of the COQ
genes (Tran and Clarke, 2007). This explains why yeast coq
mutants rarely accumulate biosynthetic Q intermediates that
may be diagnostic of the altered reaction in a particular mutant.
Indeed, yeast null coq3-to-coq9 mutants accumulate the same
early intermediate 3-hexaprenyl-4-hydroxybenzoate (HHB)
(Figure 1). Only selective mutations altering the activity of a
Coq protein without drastically affecting assembly of the Q
biosynthetic complex may lead to accumulation of intermediates
different from HHB. Only two such intermediates have been
unambiguously identified and linked to a mutation in a COQ
gene: 5-demethoxyubiquinone (DMQ6) accumulates in two
coq7 mutants, L237Stop and E233K (Padilla et al., 2004), and
3-hexaprenyl-4,5-dihydroxybenzoate accumulates in an un-
characterized coq3 mutant strain (Clarke et al., 1991). The rare
occurrence of intermediates diagnostic of the defective step in449–459, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 449
Figure 1. Current Model of the Eukaryotic
Coenzyme Q biosynthetic Pathway
The names of proteins and intermediates relevant
to this study are for S. cerevisiae. The polyprenyl
diphosphate tail is assembled from one dimethyl-
allyl pyrophosphate and 5 isopentenyl pyrophos-
phate in yeast or 9 in humans. Prenylation of
4-hydroxybenzoate (4-HB) by Coq2 yields 3-hexa-
prenyl-4-hydroxybenzoate (HHB). Seven modifi-
cations of the aromatic ring are then needed to
produce coenzyme Q6. 5-demethoxyubiquinone
(DMQ6) is the substrate of the mono-oxygenase
Coq7p. Reactions catalyzed by unidentified or
putative proteins are marked with a question
mark (?).
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fying the aromatic ring of 4-polyprenyl-3 hydroxybenzoate is still
speculative (Tran and Clarke, 2007).
Coq6p and Coq7p are two mono-oxygenases that function in
Q biosynthesis. Coq7p hydroxylates DMQ6 (Padilla et al., 2004;
Tran et al., 2006), and Coq6p may catalyze one or both of the
two remaining hydroxylation steps (Gin et al., 2003) (Figure 1).
Mono-oxygenases are widely distributed proteins that catalyze
incorporation of one oxygen atom into substrates. Dioxygen is
the source of the oxygen atom, and mono-oxygenases usually
employ a transition metal (e.g., iron or copper) or an organic
cofactor (e.g., flavin or pterin) to mediate dioxygen activation at
their active site. This activation requires two electrons, which
are provided by a reductant. NAD(P)H can directly reduce the
flavin cofactor of flavoprotein mono-oxygenases, whereas
reduction of the heme iron in cytochrome P450 type oxygenases
is accomplished by an associated reductase (Ballou et al., 2005;
Munro et al., 2007). The mammalian electron transport
machinery of mitochondrial cytochrome P450 consists of two
proteins, an NADPH-ferredoxin reductase called adrenodoxin
reductase (AdxR) and a [2Fe-2S] ferredoxin called adrenodoxin
(Adx). To date, proteins resembling mitochondrial cytochrome
P450 mono-oxygenase have not been found in yeast, yet yeast
expresses a mitochondrial ferredoxin (Yah1p) and a mitochon-
drial ferredoxin reductase (Arh1p) that are homologs of Adx
and AdxR.
The Yah1p/Arh1p system is located in the mitochondrial
matrix and is required for viability (Barros and Nobrega, 1999;
Manzella et al., 1998). Yah1p and Arh1p play an essential
role in the biogenesis of Fe-S clusters (Lange et al., 2000; Li
et al., 2001) and of heme A (Barros et al., 2002), an indispens-
able cofactor of cytochrome c oxidase. Cox15p, which cata-
lyzes the conversion of heme O to heme A, is the likely recip-
ient of electrons transferred by Yah1p (Barros et al., 2002),
whereas the recipient is still unknown for the biogenesis of
Fe-S clusters. Conserved motifs in the primary sequence of
Coq6p and Coq7p predict that these two mono-oxygenases450 Chemistry & Biology 17, 449–459, May 28, 2010 ª2010 Elsevier Ltd All rights reservedemploy a flavin and a di-iron cofactor,
respectively (Gin et al., 2003; Stenmark
et al., 2001). The oxidized flavin of
Coq6p is a two-electron acceptor,
whereas the oxidized di-iron (FeIII-FeIII)
center of Coq7p will also accept twoelectrons, but one at a time. Therefore, the putative direct
two-electron reduction of the flavin of Coq6p by hydride trans-
fer from NAD(P)H is not applicable to the di-iron center of
Coq7p. The in vivo source of electrons used by Coq7p is still
unknown, and we hypothesized that the Yah1p/Arh1p system
may fulfill this role.
In this work, we show that the Yah1p/Arh1p system is
essential for yeast Q6 synthesis. Cells depleted for Yah1p or
Arh1p accumulate specific intermediates of Q6 upstream of
DMQ6, the substrate of Coq7p. The accumulation of these early
intermediates pointed to the involvement of Yah1p/Arh1p in the
first hydroxylation reaction of Q6 biosynthesis. Surprisingly, one
of the intermediates accumulated in Yah1p-depleted cells
contains an amine group. This observation led us to show
that para-aminobenzoic acid (pABA) is the precursor of this
intermediate and that pABA enters the Q biosynthetic pathway
at the prenylation reaction catalyzed by Coq2p. Moreover,
labeling experiments proved that pABA is an in vivo precursor
of the benzoquinone ring of Q6. This new, unexpected role of
pABA has been overlooked since the discovery of 4-HB as
the precursor of the benzoquinone ring of Q more than 40 years
ago.
RESULTS
The Mitochondrial Ferredoxin Yah1p and Its Associated
Reductase Arh1p Are Essential for Q6 Biosynthesis
To test the possible role of the mitochondrial ferredoxin Yah1p
in Q6 biosynthesis, we used the strain Gal-YAH1 in which the
native YAH1 promoter was replaced by the GAL10 promoter
(Lange et al., 2000). Therefore, the expression of the essential
YAH1 gene in the Gal-YAH1 strain is under the control of a
galactose-inducible promoter (Lange et al., 2000). When YAH1
expression was repressed by cultivating the Gal-YAH1 strain
in a glucose-containing medium, we noted a strong depletion
of the Q6 content of the cells together with that of DMQ6
(Figure 2A). Q6 and DMQ6 were detected electrochemically
Figure 2. The Yeast Ferredoxin/Ferredoxin
Reductase System Is Required for Q6
Biosynthesis
(A) Gal-YAH1 cells were cultivated for 18 hr in SC
medium containing either 2% galactose (gal) or
2% glucose (glu). Extracts of 10 mg (gal) and
20 mg (glu) of cells were analyzed by electrochem-
ical detection coupled to HPLC (HPLC-ECD).
Elution positions of the Q4 standard, of DMQ6
and Q6 and of the electroactive compound (?)
accumulated in Yah1p-depleted cells are indi-
cated on the electrochromatogram.
(B) WT and Gal-YAH1 cells containing an empty
vector (vec) or the YAH1 ORF were grown in
SC-2% glucose for 18 hr. Extracts of 8 mg of cells
were analyzed by HPLC-ECD.
(C) WT and Gal-ARH1cells were cultivated for 40 hr
in SC-2% glucose in order to deplete Arh1p to
critical levels. Mitochondria were prepared and
analyzed for Arh1p and Yah1p by immunostaining.
Porin (Por1p) served as a loading control.
(D) Mitochondrial extracts (50 mg of mitochondrial
proteins) were analyzed by HPLC-ECD. Mito-
chondria were purified from WT, Gal-YAH1, and
Gal-ARH1 cells grown in SC-2% glucose.
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detected an additional electroactive compound eluting at
around 610 s that was absent from the galactose-grown cells
(Figure 2A). The striking decrease of Q6 does not result from
dying cells because the cells were viable at the end of the
glucose culture, as assessed by determining the colony-forming
units on galactose medium. Introduction of a plasmid carrying
the YAH1 gene in the Gal-YAH1 strain restored wild-type Q6
levels in glucose-grown cells and abolished the accumulation
of the electroactive compound (Figure 2B). To verify that the
[2Fe-2S] cluster of Yah1p was required for Q6 generation, we
constructed mutant alleles of Yah1p in which conserved Fe-S
cysteine ligands (C103 and C106) are mutated to alanine (see
Figure S1 available online) (Xia et al., 1996). The electrochroma-
tograms of extracts from glucose-grown Gal-YAH1 strains
containing an empty vector and from C103A or C103-106S
mutants of Yah1p were similar, with an accumulation of the
newly detected metabolite, showing that these cysteines are
essential for Yah1p function (Figure 2B and data not shown).
The Fe-S center of Yah1p is reduced by electrons provided
by the ferredoxin reductase Arh1p which is also an essential
protein (Manzella et al., 1998). To corroborate the observation
that Yah1p is required for Q6 biosynthesis, we generated a
Gal-ARH1 strain in which the expression of ARH1 is repressed
by growth in glucose medium. After growth of the Gal-ARH1
strain in glucose medium, Arh1p was undetectable in purified
mitochondria, but Yah1p steady-state level was only mildly
decreased (Figure 2C). These mitochondria showed little Q6
and accumulated the electroactive compound found inChemistry & Biology 17, 449–459, May 28, 2010Yah1p-depleted mitochondria (Fig-
ure 2D). Altogether, these results show
that the absence of a functional ferre-
doxin/ferredoxin reductase system
strongly depletes cellular and mitochon-drial levels of Q6 and promotes the accumulation of a novel
compound.
A Strain Deficient in Yah1p Accumulates
3-Hexaprenyl-4-Aminophenol, a Product Derived
from the Q6 Biosynthetic Pathway
We attempted to identify the origin and nature of the electroac-
tive compound accumulating in Yah1p-deficient cells and found
that it is different from DMQ6, the only intermediate of Q6 biosyn-
thesis observed by electrochemical detection so far. Deletion of
COQ5 or COQ7, two genes essential for Q6 biosynthesis, abol-
ishes formation of Q6 and results in the accumulation of HHB
because many Coq proteins of the Q biosynthetic complex are
unstable in these mutants (Figure 1) (Tran and Clarke, 2007).
Deletion of COQ5 or COQ7 in the Gal-YAH1 strain prevented
the accumulation of the electroactive compound upon depletion
of Yah1p (Figure 3A and data not shown). This result suggests
that the electroactive compound is part of the Q6 pathway and
is formed downstream of HHB.
To determine whether the compound is produced during the
Q6 biosynthetic pathway or is a degradation product of Q6, we
exploited a strain that accumulates mostly DMQ6 instead of
Q6. This strain contains a chromosomal insertion of a sequence
coding for a triple hemagglutinin (3HA) epitope tag on the 30 end
of COQ7. The presence of the 3HA epitope on the C terminus of
Coq7p likely causes the partial inactivation of the protein, as evi-
denced by the accumulation of large amounts of DMQ6 as
compared to Q6 (Figure 3B). Depletion of Yah1p in a Gal-YAH1
COQ7-3HA strain resulted in a strong decrease of DMQ6 and stillª2010 Elsevier Ltd All rights reserved 451
Figure 3. 3-Hexaprenyl-4-Aminophenol Is
Derived from Q6 Biosynthesis
(A) Gal-YAH1 cells and Gal-YAH1 coq5D cells
were inoculated from a culture in SC-2% galac-
tose and 0.4% glucose into SC-2% glucose and
were grown for 18 hr. Extracts of 30 mg of cells
were analyzed by HPLC-ECD.
(B) WT, COQ7-3HA, and Gal-YAH1 COQ7-3HA
cells were grown in YPD for 12 hr. Extracts of
45 mg (WT), 60 mg (COQ7-3HA), and 120 mg
(Gal-YAH1 COQ7-3HA) of cells were analyzed by
HPLC-ECD.
(C) 1H NMR spectrum of the purified C36H55NO
molecule in deuterated methanol is shown.
(D) Superimposition of the aromatic regions of
the 1H NMR spectrum of the purified C36H55NO
molecule displayed in (C) and of the 1H NMR
spectrum of commercial 3-methyl-4-aminophenol
(3M4Aphe).
(E) Chemical structure of 3-hexaprenyl-4-amino-
phenol and numbering of the aromatic carbon
atoms used in the rest of the study.
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eluting at around 610 s (Figure 3B). This result demonstrates
that this compound is not a degradation product of Q6 and
strongly suggests that it originates from Q6 biosynthesis at
a step prior to the hydroxylation of DMQ6 catalyzed by Coq7p.
We purified the compound in its reduced form, analyzed it by
high-resolution mass spectrometry, and obtained an m/z ratio of
518.43610 (M+H+). The molecular mass was submitted to
different chemical formula prediction software; C36H55NO was
the elemental composition that fitted best (M = C36H55NO:
517.42836; observed mass, 517.42828; ppm, 0.2) when
C,H,N,O,P,S atoms were included in the calculation. To deter-
mine whether the C36H55NO molecule contains a hexaprenyl
moiety like Q6, we obtained two fragmentation spectra of the
518.4 molecular ion (M+H+) on different spectrometers. The
fragments at m/z 122 and 162 are consistent with carboxyami-
notropylium and carboxyaminopyrilium ions, respectively
(Figure S2A). Tropylium and pyrilium ions are typically observed
upon fragmentation of Q6 (m/z 197 and 237) and DMQ6 (m/z 167452 Chemistry & Biology 17, 449–459, May 28, 2010 ª2010 Elsevier Ltd All rights reservedand 207) (Padilla et al., 2004). The frag-
mentation observed on the spectrum in
Figure S2B is consistent with the succes-
sive loss of methine, methylene, or methyl
groups of the hexaprenyl chain, the light-
est fragment (162.0915) corresponding to
C10H12NO. Both fragmentation spectra
are indicative of the presence of a hexap-
renyl chain in the C36H55NO molecule.
We next characterized the purified
C36H55NO molecule by NMR spectros-
copy. The resulting 1H NMR spectrum
shows well-defined peaks, with some of
them easily attributable to the hexaprenyl
moiety (methyl, methylene, and vinylic
protons) (Figure 3C and Experimental
Procedures). The aromatic region shows
three massifs (6.67 to 6.61 ppm, 6.57 to6.54 ppm, and 6.52 to 6.46 ppm) of equal intensity all situated
at rather high field for aromatic protons (Figure 3D). These
results strongly suggest the presence of three electro-donating
substituents on the aromatic ring. Moreover, the observed multi-
plicity associated with the value of the coupling constants
unambiguously establishes both meta and para substitutions.
Finally, the aromatic region of the spectrum was compared
with that of the commercially available 3-methyl-4-aminophenol
(Figure 3D). Both spectra were almost superimposable, with
identical pattern and coupling constants and slightly different
chemical shifts. The UV-visible absorption spectra of the
reduced and oxidized forms of the purified compound and of
3-methyl-4-aminophenol show identical absorbance maxima
(Figures S2C and S2D). All these results unambiguously identify
3-hexaprenyl-4-aminophenol as the electroactive compound
accumulated in Yah1p-deficient cells (Figure 3E). For the sake
of simplicity, the numbering of the aromatic carbon atoms of
the different Q6 intermediates throughout this article will be as
in Figure 3E.
Figure 4. pABA and 4-HB Compete for
Prenylation by Coq2p
(A) Gal-YAH1 cells (50 mg) grown for 18 hr in YPD
supplemented with pABA were extracted and
analyzed by HPLC-ECD.
(B) Gal-YAH1 cells (30 mg) grown for 18 hr in
SC-2% glucose supplemented with 4-HB were
extracted and analyzed by HPLC-ECD.
(C) coq5D cells were grown in 30 mL of YPD with
the indicated concentration of pABA or 4-HB.
Lipid extracts were treated with diazomethane
and analyzed by HPLC. The elution profile at
273 nm and the elution position and chemical
structure of 3-hexaprenyl-4-aminobenzoic acid
methylester (HABme) and 3-hexaprenyl-4-hydrox-
ybenzoic acid methylester (HHBme) are shown.
Areas of the peaks at 273 nm for HABme and
HHBme are shown in the inset. A.U., arbitrary
units.
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and Competes with 4-HB for Prenylation by Coq2
The presence of a nitrogen atom in a product synthesized in vivo
by the Q6 biosynthetic pathway was surprising. Indeed, C, H, and
O atoms are the only constituents of the different intermediates
of Q biosynthesis described to date (Figure 1). pABA is structur-
ally close to 4-HB, the precursor of the aromatic ring of Q
(Figure 1). We therefore hypothesized that the 3-hexaprenyl-4-
aminophenol synthesized in the Yah1p-deficient strain might
originate from pABA. The accumulation of 3-hexaprenyl-4-ami-
nophenol increased in the Gal-YAH1 strain upon addition ofChemistry & Biology 17, 449–459, May 28, 2010pABA to YP-glucose (YPD) medium (Fig-
ure 4A), showing that pABA is the pre-
cursor of 3-hexaprenyl-4-aminophenol.
We also consistently detected more
3-hexaprenyl-4-aminophenol when the
Gal-YAH1 strain was cultured in glucose
synthetic complete (SC-2% glu) medium
compared to YPD (compare Figures 4A
and 4B). This is likely because pABA is
an ingredient of synthetic medium at
0.2mg/L.
pABA being a precursor of 3-hexap-
renyl-4-aminophenol suggested that
pABA is prenylated by the polyprenyl
transferase Coq2p, which is known to
prenylate 4-HB. Decreased levels of
3-hexaprenyl-4-aminophenol were ob-
served in the Gal-YAH1 strain when
4-HB was added to the culture medium
(Figure 4B), suggesting a competition
between pABA and 4-HB for prenylation
by Coq2p. The addition of 3,4-dihydroxy-
benzoic acid was without an effect on the
accumulation of 3-hexaprenyl-4-amino-
phenol (data not shown).
A coq5D strain accumulates HHB, the
product of the prenylation of 4-HB cata-
lyzed by Coq2p (Figure 1) (Tran andClarke, 2007). Esterification of HHB with diazomethane stabilizes
HHB and facilitates its detection by mass spectrometry (Poon
et al., 1995). 3-Hexaprenyl-4-hydroxybenzoic acid methylester
(HHBme) (M = C38H56O3: 560.42291; observed mass,
560.42113; ppm, 3.2) was detected spectroscopically eluting
at 620 s in chromatograms of diazomethane-treated extracts
of the coq5D strain (Figure 4C), and was found to be absent
from extracts of the WT strain or from untreated extracts (data
not shown). pABA supplementation increased the accumulation
of 3-hexaprenyl-4-aminobenzoic acid methylester (HABme)
(M = C38H57NO2: 559.43890; observed mass, 559.43931; ppm, 0.7)ª2010 Elsevier Ltd All rights reserved 453
Figure 5. Yah1p-Deficient Cells Also Accu-
mulate 3-Hexaprenyl-4-Hydroxyphenol
(A) Gal-YAH1 cells (20 mg) grown for 18 hr in YPD
were extracted and analyzed by HPLC-ECD.
(B) Chemical structure of 3-hexaprenyl-4-hydroxy-
phenol.
(C) Gal-YAH1 cells (30 mg) grown for 18 hr in YPD
supplemented with 1 or 10 mg/L 4-hydroxyben-
zoic acid (4-HB) or para-aminobenzoic acid
(pABA) were extracted and analyzed by HPLC-
ECD. 3-hexaprenyl-4-aminophenol elutes at
around 610 s and 3-hexaprenyl-4-hydroxyphenol
at around 800 s and areas of the peaks are shown
in the inset. A.U., arbitrary units.
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strain (Figure 4C). HABme was also absent from extracts of the
WT strain or from untreated extracts (data not shown). It is
apparent in Figure 4C that pABA supplementation increases
HABme and decreases HHBme, whereas 4-HB supplementation
increases HHBme and decreases HABme. This finding shows
that pABA and 4-HB are competing substrates for the prenyla-
tion reaction catalyzed by Coq2p.
Concomitant Accumulation of 3-Hexaprenyl-4-
Hydroxyphenol and 3-Hexaprenyl-4-Aminophenol
by the Yah1p-Deficient Strain
SC medium contains pABA which efficiently competes with
4-HB for the prenylation reaction. To check whether a compound
originating from 4-HB may form within the Yah1p-deficient
strain, we cultured the Gal-YAH1 strain in YPD instead of SC
medium (Figure 2A). Together with 3-hexaprenyl-4-aminophenol
at 610 s, we detected an electroactive compound eluting at 800 s
in extracts of the Gal-YAH1 strain cultured in YPD (Figures 4A
and 5A). The purified compound yielded a pseudomolecular
ion at m/z 519.41962 (M+H+) upon high-resolution mass spec-
trometry analysis. This value is consistent with a chemical454 Chemistry & Biology 17, 449–459, May 28, 2010 ª2010 Elsevier Ltd All rights reservedformula C36H54O2 (M = C36H54O2:
518.41235; observed mass, 518.4118;
ppm, 1.1). The fragmentation spectrum
supports the presence of a hexaprenyl
tail in the molecule with fragments corre-
sponding to loss of methine, methylene,
or methyl groups of the hexaprenyl chain
(Figure S3A). UV-Vis spectra of the
C36H54O2 molecule are similar to the
ones of methyl-1,4-benzoquinone (Fig-
ures S3B and S3C, respectively). These
results, in addition to the fact that the
C36H54O2 molecule is not formed in either
the Gal-YAH1 coq5D or Gal-YAH1 coq7D
cells (data not shown), strongly suggest
that 3-hexaprenyl-4-hydroxyphenol is
the electroactive compound eluting at
800 s (Figure 5B).
This conclusion was further substan-
tiated by the finding that 4-HB is the
precursor of 3-hexaprenyl-4-hydroxy-
phenol. Indeed, the addition of 4-HB toYPD medium increased 3-hexaprenyl-4-hydroxyphenol and
decreased 3-hexaprenyl-4-aminophenol in the Yah1p-deficient
strain (Figure 5C). In contrast, the addition of pABA increased
the quantity of 3-hexaprenyl-4-aminophenol, as noted earlier
(Figure 4A), but also decreased the production of 3-hexap-
renyl-4-hydroxyphenol (Figure 5C). This competition between
pABA and 4-HB for the formation of 3-hexaprenyl-4-aminophe-
nol and 3-hexaprenyl-4-hydroxyphenol parallels the one
observed for the biosynthesis of 3-hexaprenyl-4-aminobenzoic
acid and 3-hexaprenyl-4-hydroxybenzoic acid (Figure 4C).
pABA Is a Precursor of Q6
We have shown that 3-hexaprenyl-4-aminophenol and 3-hexap-
renyl-4-aminobenzoic acid originate from pABA, suggesting that
pABA enters the Q6 biosynthetic pathway (Figures 4A and 4C).
To check whether pABA may be a precursor of Q6 like 4-HB,
we synthesized U-(13C)-pABA from U-(13C)-toluene in three
steps (Figure S4 and Supplemental Experimental Procedures).
As expected, culture of the Gal-YAH1 strain in YPD containing
U-(13C)-pABA predominantly yielded 13C6-labeled 3-hexap-
renyl-4-aminophenol at m/z 524.4 (data not shown). A WT strain
was cultured in YPD supplemented with 2 mg/L of U-(13C)-pABA
Figure 6. pABA Is a Precursor of Q6
(A) Mass spectrum of Q6 purified from a W303 WT strain grown in YPD medium
supplemented with 2 mg/L of U-(13C)-pABA.
(B) The W303 WT strain was grown in synthetic medium, synthetic medium
lacking pABA, or rich (YP) medium, with 2% galactose as a carbon source.
Cells were harvested in late exponential growth phase, and lipids were
extracted. Q6 (pmoles per mg of wet weight cell pellet) was quantified by
HPLC-ECD, and DMQ6 represented less than 10% of Q6 in all samples.
Data are the average of at least 3 independent cultures, and error bars
represent the standard error of the mean.
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showed two peaks of comparable abundance at m/z 591.4
and 597.4 (Figure 6A), corresponding to unlabeled Q6 and
13C
ring-labeled Q6, respectively. This result clearly shows that
pABA is a precursor of Q6 in yeast. For pABA to be converted
into Q6, the amine group must be replaced by an hydroxyl group
during the Q6 biosynthetic pathway after the formation of 3-hex-
aprenyl-4-aminobenzoate. The COQ7-3HA strain mostly accu-
mulated DMQ6 instead of Q6 (Figure 3B). The mass spectrum
of DMQ6 purified from the COQ7-3HA strain grown in YPD sup-
plemented with 2 mg/L of U-(13C)-pABA displayed two main ions
(M+H+) m/z 561.43036 and 567.45111, which correspond to
unlabeled DMQ6 (M = C38H56O3: 560.42294; observed mass,
560.42254; ppm, 0.7) and to 13C ring-labeled DMQ6 (M =
13C6
12C32H56O3: 566.44307; observed mass, 566.44329; ppm,
0.4) respectively. This result demonstrates that the NH2-to-OH
substitution occurs prior to the hydroxylation of DMQ6 by
Coq7p, the penultimate step of Q6 biosynthesis.
We next cultured the W303 WT strain in synthetic medium
lacking pABA. To our surprise, cells grown in pABA-free medium
accumulated 8–10-fold less Q6 than did cells grown in rich (YP)
medium or in synthetic medium (Figure 6B). The addition of
0.2 mg/L of pABA to pABA-free medium yields synthetic medium
and restored normal levels of Q6 (Figure 6B). pABA and 4-HB
were equally efficient to support Q6 synthesis when added to
pABA-free medium. These results illustrate our conclusion that
pABA is a precursor of Q6 and support the idea that most of
the Q6 synthesized by yeast grown in synthetic medium actually
originates from the pABA present in the growth medium. To
determine whether S. cerevisiae uses endogenous pABA for
Q6 biosynthesis, we cultured the Gal-YAH1 strain in pABA-free
medium containing 2% galactose and then in pABA-free
medium containing 2% glucose. 3-Hexaprenyl-4-aminophenol
was detected in cell lipid extracts (data not shown), showing
that endogenously synthesized pABA enters the Q biosynthetic
pathway.
DISCUSSION
In this work, we show that the mitochondrial ferredoxin Yah1p
and its reductase Arh1p, the yeast homologs of mammalian
Adx and AdxR, are essential for Q biosynthesis in yeast. Strains
depleted for any of these two essential proteins have a strongly
reduced content of Q6 and accumulate 3-hexaprenyl-4-amino-
phenol and 3-hexaprenyl-4-hydroxyphenol (Figure 5C). 3-hex-
aprenyl-4-aminophenol results from the prenylation of pABA by
Coq2p, whereas prenylation of 4-HB, the long-known ring
precursor of Q, will ultimately produce 3-hexaprenyl-4-hydroxy-
phenol (Figure 7, paths 1 and 4, respectively). pABA and 4-HB
differ only by one substituent of benzoic acid, an amine or an
hydroxyl group, and both molecules originate in E. coli and yeast
from chorismate, a product of the shikimate pathway. In agree-
ment with our results, pABA has previously been shown to be
prenylated by orthologs of Coq2p in E. coli and rat, as evidenced
by the observation of 3-polyprenyl-4-aminobenzoic acid (Hamil-
ton and Cox, 1971) (Alam et al., 1975). pABA can therefore enter
the Q biosynthetic pathway in many organisms, but are these
organisms capable of converting 3-polyprenyl-4-aminobenzoic
acid into Q? Our work clearly shows that, in yeast, 3-hexap-Chemistry & Biology 17,renyl-4-aminobenzoic acid is converted to Q6 since addition of
U-(13C)-pABA to the growth medium of WT yeast strain
promotes the biosynthesis of 13C6 labeled Q6 (Figure 6A and
Figure 7, path 2). pABA is likely not a precursor of Q in E. coli
because a mutant strain deficient in chorismate synthetase
activity synthesized Q upon supplementation of the growth
medium with 4-HB but not with pABA, despite the formation of
3-polyprenyl-4-aminobenzoic acid (Hamilton and Cox, 1971).
Our results with yeast warrant a thorough investigation to deter-
mine whether mammalian cells can convert pABA into Q. In vitro
experiments by Alam et al. (1975) on rat liver demonstrated that
pABA is converted to 3-polyprenyl-4-aminobenzoic acid and
suggested that this compound was further modified although
not into Q. Therefore, pABA has been considered an inhibitor
of Q biosynthesis in mammals, but only a limited decrease of
Q was observed in cancer cells upon culture in a high concentra-
tion of pABA (Brea-Calvo et al., 2006).449–459, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 455
Figure 7. Dysfunction of the Q6 Biosynthetic Pathway
in Yah1p/Arh1p-Depleted Yeast Cells
‘‘R’’ stands for the hexaprenyl chain. Reactions blocked in the
absence of Yah1p/Arh1p are shown in red. The different series
of reactions are numbered as paths 1 to 4. Coq2p catalyzes
the hexaprenylation of pABA (blue) and 4-HB to form 3-hexap-
renyl-4-aminobenzoic acid and 3-hexaprenyl-4-hydroxyben-
zoic acid, respectively. In a WT strain, the conversion of 3-hex-
aprenyl-4-aminobenzoic acid into Q6 requires the NH2-to-OH
conversion on C4, which occurs prior to DMQ6 (path 2). The C5
hydroxylation of 3-hexaprenyl-4-amino/hydroxybenzoic acid
catalyzed by an unidentified oxygenase is blocked in the
absence of Yah1p/Arh1p (path 2 and 3). In this case, the
normal Q6 biosynthetic pathway (path 2 and 3) branches off
via decarboxylation of 3-hexaprenyl-4-aminobenzoic acid
(path 1) and 3-hexaprenyl-4-hydroxybenzoic acid (path 4).
Coq6p then synthesizes 3-hexaprenyl-4-aminophenol
(path 1, framed) and 3-hexaprenyl-4-hydroxyphenol (path 4,
framed). 3-hexaprenyl-4-amino/hydroxyphenol accumulates
because Coq5p does not catalyze the C2 methylation and
Coq7p does not catalyze the C6 hydroxylation in the absence
of Yah1p/Arh1p (see Discussion).
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when yeast is cultured in pABA-free medium, it is reasonable
to postulate that most of the Q6 produced by yeast cultured in
SC medium originates from the pABA present in this growth
medium. Our results suggest that, in pABA-free medium, the
rate-limiting step of Q6 biosynthesis is the availability of the
ring precursors of Q, 4-HB and pABA. Endogenous levels of
these molecules allow the synthesis of only 1.4 pmoles of
Q6/mg of wet cells under our nonrepressive culture conditions.
One can then question the physiological significance of the
high levels of Q6 (12–16 pmoles of Q6/mg of wet cells) synthe-
sized by yeast grown in SC medium or rich medium. Actually,
several authors have shown that only a small percentage of the
Q6 synthesized in these growth media is sufficient to sustain
respiratory growth (Mollet et al., 2008; Tran et al., 2006), suggest-
ing that, under normal conditions, Q6 is in vast excess for its
function as an electron carrier in the respiratory chain. Our456 Chemistry & Biology 17, 449–459, May 28, 2010 ª2010 Elsevier Ltd All rights reresults also provide a possible explanation as to
why, contrary to E. coli, mutants affecting 4-HB
synthesis may not abrogate yeast Q6 biosynthesis
and therefore not result in a respiratory deficient
phenotype. Previously, authors have speculated
that yeast may produce 4-HB by multiple ways—
from chorismate via the chorismate pyruvate-lyase
reaction similar to the E. coli pathway, and from
tyrosine like in higher eukaryotes (Clarke, 2000).
However, none of the enzymes responsible for
these reactions has been identified in yeast. The
fact that pABA can be used in Q6 biosynthesis
like 4-HB and that pABA is present in standard
yeast culture media imply that pABA may support
biosynthesis of Q6 in a yeast mutant blocked for
the synthesis of 4-HB when cultured in standard
conditions.
The conversion of pABA into Q6 suggests an
additional step in Q6 biosynthesis: the replace-
ment of the amine by an hydroxyl group at C4(Figure 7, path 2). This reaction certainly takes place down-
stream of the hexaprenylation reaction catalyzed by Coq2p
because 3-hexaprenyl-4-aminobenzoic acid was detected in a
coq5D strain (Figure 4C). The formation of 13C6-DMQ6 upon
supplementation of the growth medium with U-(13C)-pABA
proves that the C4 aromatic NH2-to-OH conversion occurs prior
to the formation of DMQ6. The accumulation of 3-hexaprenyl-4-
aminophenol in the Yah1p-depleted strain suggests that this
reaction occurs after the C1 hydroxylation step. Alternatively,
the presence of the amine group at this stage may simply result
from the lack of hydroxylation of the adjacent C5 position.
Indeed, on the basis of the example of bacterial anthranilate
and aniline dioxygenases, which catalyze the conversion of
aromatic amines into ortho-catechols (Beharry et al., 2003;
Ang et al., 2007), the NH2-to-OH substitution on C4 may occur
together with the hydroxylation on C5. The NH2-to-OH conver-
sion reaction is chemically challenging and future studies willserved
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thesis.
What is the role of Yah1p/Arh1p in Q6 biosynthesis? Defi-
ciency in either of these two proteins results in accumulation
of 3-hexaprenyl-4-amino/hydroxyphenol. To form 3-hexaprenyl-
4-amino/hydroxyphenol from 3-hexaprenyl-4-amino/hydroxy-
benzoic acid, the decarboxylation and hydroxylation at position
1 must occur without hydroxylation of C5 (Figure 7, paths 1
and 4). Therefore, the most upstream reaction of the Q6 biosyn-
thetic pathway to be inhibited in the absence of Yah1p/Arh1p is
the C5 hydroxylation of 3-hexaprenyl-4-amino/hydroxybenzoic
acid. The identity of the mono-oxygenase that catalyzes the
C5 hydroxylation is currently unknown. Coq6p has been initially
proposed to catalyze either the C5 or C1 hydroxylations or both
(Gin et al., 2003). Our results strongly argue for the involvement
of Coq6p in only one of the two reactions because the C1
hydroxylation still proceeds in the Yah1p/Arh1p-depleted
strains, whereas the C5 hydroxylation does not. Coq6p se-
quence contains conserved motifs characteristic for flavin-
dependent mono-oxygenases such as 4-hydroxybenzoate
hydroxylase (Gin et al., 2003). Reduction of the FAD cofactor at
the active site of 4-hydroxybenzoate hydroxylase has been
extensively studied and has been shown to proceed via a direct
hydride transfer from NADPH (Ballou et al., 2005). By analogy,
NAD(P)H is the likely electron donor to Coq6p, making the
hydroxylation catalyzed by Coq6 independent of the Yah1p/
Arh1p reducing system. We thus propose that the C1 hydroxyl-
ation, which is unaffected by depletion of Yah1p/Arh1p, is cata-
lyzed by Coq6p (Figure 7). This point is difficult to prove because
a coq6D strain, like the other coq3 to coq9 null mutants, accu-
mulates only HHB because of the instability of the Q biosynthetic
complex (Gin et al., 2003; Hsieh et al., 2007). The involvement of
Coq6p in the C1 hydroxylation implies that the C5 hydroxylation
is catalyzed by an unknown oxygenase that may require electron
transport machinery such as Yah1p/Arh1p. This scenario would
explain why the C5 hydroxylation is abrogated upon depletion of
Yah1p or Arh1p.
How do we explain that the reactions after the C1 hydroxyl-
ation (C2 methylation by Coq5p, C6 hydroxylation by Coq7p,
and O6 methylation by Coq3p) do not take place in the Yah1p-
depleted strain (Figure 7, paths 1 and 4)? Yah1p is likely not
directly required for the methylation reactions because (1) meth-
ylations are nonredox reactions, and (2) they use S-adenosyl-
methionine (SAM) as a methyl donor, a cofactor whose synthesis
is cytosolic and does not require Fe-S-containing enzymes
whose maturation is generally dependent on Yah1p (Lange
et al., 2000). The two O-methylation reactions can not proceed
because of the lack of the two corresponding hydroxylations
(C5 and C6). The absence of methylation at C2 may be explained
in that the C2 carbon will be insufficiently enriched in electrons
for an efficient nucleophilic attack to the methyl group of SAM
in the absence of the methoxy group on C5. Alternatively, the
absence of this methoxy group may prevent substrate binding
and recognition by Coq5p. Finally, we envision at least two
reasons that could explain the inactivity of Coq7p in the absence
of Yah1p/Arh1p. On the one hand, Coq7p may not bind
a substrate that lacks the C5 methoxy group and the C2 methyl
group. On the other hand, Yah1p/Arh1p may provide electrons
for the reduction of the di-iron center of the mono-oxygenaseChemistry & Biology 17,Coq7p, a scenario that was the founding hypothesis of this
study. We could not gain any information on this point because
Yah1p/Arh1p is required for the hydroxylation of 3-hexaprenyl-
4-amino/hydroxybenzoic acid, a reaction upstream of the
hydroxylation of DMQ6 which is catalyzed by Coq7p. Further
work is needed to test whether Yah1p/Arh1p is the physiological
reducing system of Coq7p. Answering this question will probably
require the development of an in vitro assay for Coq7p function,
a task highly challenging given that, in vivo, Coq7p is part of the
Q biosynthetic complex (Tran and Clarke, 2007).
In conclusion, our study has unraveled that pABA serves as
a precursor of Q6 similar to 4-HB whose role in Q biosynthesis
was identified more than 40 years ago. We also demonstrated
that the yeast Adx/AdxR homologs Yah1p/Arh1p are required
for the first hydroxylation reaction of the yeast Q6 biosynthetic
pathway, which represents a new function for these proteins.
In the light of these results, it seems important to evaluate
whether these new actors of yeast Q6 biosynthesis play a role
in mammalian Q biosynthesis.SIGNIFICANCE
Coenzyme Q is a redox-active lipid that functions in electron
transport chains in cellular membranes and also has an
important antioxidant function. Q is a prenylated benzoqui-
none for which biosynthesis starts with the assembly of a
polyprenyl chain and its conjugation to 4-HB, the precursor
of the benzoquinone moiety (Turunen et al., 2004). Here, we
demonstrate that yeast can convert pABA into Q making of
pABA a new precursor of Q, like the long-known 4-HB. Our
finding thus implies that an aromatic NH2-to-OH conversion
must occur to synthesizeQ frompABA. The reducing system
formed by the mitochondrial ferredoxin Yah1p and its asso-
ciated reductase Arh1p is essential for Fe-S cluster biosyn-
thesis (Lange et al., 2000; Li et al., 2001). This study identifies
a new function for Yah1p and Arh1p in Q biosynthesis in
yeast. Studies on yeast have provided the basis for the eluci-
dation of the eukaryotic biosynthesis of Q. Sequence iden-
tity to yeast genes and complementation of yeast mutants
have allowed the characterization of genes implicated in
human Q biosynthesis. Mutations in five human genes
have been shown to cause primary Q deficiency, which
results in encephalomyopathy and severe infantile multisys-
temic disease. It will be of interest to define whether pABA
and the orthologs of Yah1p and Arh1p are involved in
mammalian Q biosynthesis.EXPERIMENTAL PROCEDURES
Yeast Strains and Culture Conditions
Yeast strains used in this study are listed in Table S1. Yeast strains were trans-
formed using lithium acetate. A 3HA epitope tag was inserted on the 30 end of
COQ7 ORF by PCR, as described elsewhere (Longtine et al., 1998), to create
the COQ7-3HA strain. This strain was crossed with the Gal-YAH1 gene to
isolate the COQ7-3HA Gal-YAH1 strain by selecting the corresponding
markers after tetrad dissection. The coq5D Gal-YAH1 and coq7D Gal-YAH1
strains were obtained in a similar way. In Gal-ARH1, the upstream region
from ARH1 was exchanged for the galactose-inducible GAL-L promoter by
PCR mediated DNA replacement (Janke et al., 2004).Yeast media were sup-
plemented with either 2% glucose or 2% galactose. Synthetic medium449–459, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 457
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pABA Is a Precursor of Yeast Coenzyme Qconsisted of 1.7 g/L YNB and 5g/L ammonium sulfate and the appropriate
nutrients to complement strains auxotrophies. Synthetic complete (SC)
medium was obtained by adding 2 g/L Drop-out mix Synthetic minus Ade,
His, Leu, Trp, and Ura (US Biological) to synthetic medium. YNB without
pABA and folate was from MP Biomedicals and was supplemented with
5 mg/L folate. Rich YP medium was prepared as described elsewhere (Sher-
man, 2002). Gal-YAH1 and Gal-ARH1 strains were maintained and precultured
on galactose medium. Depletion of Yah1p was accomplished by diluting
300-fold the preculture into glucose containing medium and growing the cells
for 18 hr at 30C. Depletion of Arh1p required two subsequent dilutions in
glucose medium.
Plasmids
YAH1 ORF with its own promoter (380 bp) and terminator (150 bp) was cloned
into pRS416 using XhoI and SacI. This vector served as a template to generate
the C103A and C103,106S mutants by site-directed mutagenesis. Sequencing
was used to confirm cloning products in all created vectors. The E. coli strain
DH5a was used for plasmid DNA amplification.
Miscellaneous Biochemical Analysis
Isolation of yeast mitochondria and immunostaining were performed as
described elsewhere (Diekert et al., 2001; Harlow and Lane, 1988).
Lipid Extraction and Quantification of Electroactive Compounds
by HPLC-ECD
Lipid extraction and analyses of quinone content were performed essentially
as described elsewhere (Tran et al., 2006). Glass beads (100 mL), 50 mL H2O,
and Q4 (used as an internal standard) were added to mitochondria (100 mg
mitochondrial proteins) or to cell pellets (40 mg wet weight). Tubes were wrap-
ped in foil, and lipids were extracted by adding 0.6 mL of methanol and 0.4 mL
of petroleum ether and by vortexing for 3 min. The phases were separated by
centrifugation (3 min at 10003 g at 4C). The upper petroleum ether layer was
transferred to a fresh tube. Petroleum ether (0.4 mL) was added to the glass
bead and methanol–containing tube, and the extraction was repeated twice
more. The petroleum ether layers were combined and dried under nitrogen.
The lipids were resuspended in 100 mL mobile phase (98% methanol,
20 mM lithium perchlorate), and aliquots were analyzed by reversed-phase
high-pressure liquid chromatography with a C18 column (Betabasic-18,
5 mm, 4.6 3 150 mm, Thermo Scientific) at a flow rate of 1 mL/min. Quinones
were quantified with an ESA Coulochem II electrochemical detector and
a 5011A analytical cell (E1, 500 mV; E2, 500 mV). Hydroquinones present
in samples were oxidized with a precolumn 5020 guard cell set in oxidizing
mode (E, +550 mV). The maximum output signal of the analytical electrode
E2 was set to +10 V and was recorded by a four-channel signal recorder
USB10 (Velleman instruments). The Q4 external standard was used to correct
for sample loss during the organic extraction on the basis of its recovery
(always greater than 85%).
NMR Analysis of 3-Hexaprenyl-4-Aminophenol
NMR spectra were recorded on a Bruker EMX 300 MHz spectrometer. 3-hex-
aprenyl-4-aminophenol: assignable protons: 1H NMR (CD3OD) 6.64 (d,
3J =
8.4 Hz, H2N-C-CH, 1H), 6.55 (d,
4J = 2.8 Hz, H2N-C-CH-CH-C(OH)-CH, 1H),
6.49 (dd, 3J = 8.4 Hz, 4J = 2.8 Hz, H2N-C-CH-CH, 1H), 5.27 (t,
3J = 7.1 Hz,
Ar-CH2-CH, 1H), 5.12 (m, vinylic H, 5H), 3.21 (d,
3J = 7.2 Hz, benzylic H),
2.25-1.90 (m, vinylic CH2 and CH3).
Esterification and Analysis of 3-Hexaprenyl-4-Aminobenzoate
and 3-Hexaprenyl-4-Hydroxybenzoate
Dried lipid extracts from yeast cells (700 mg wet weight) were resuspended in
400 mL of anhydrous diethyl ether. One hundred fifty microliters of diazome-
thane (0.2 M in diethyl ether) was added, the mixture was incubated for
8 min at room temperature, and the reaction was quenched by adding 10 mL
of glacial acetic acid. Samples were dried under nitrogen, and HPLC analysis
was performed as described for quinone content quantification except that the
signal recorded was the absorbance at 273 nm.
Mass Spectrometry
For high-resolution mass spectrometry analyses, samples in methanol were
diluted in 90% acetonitrile and 0.2% formic acid and were infused into the458 Chemistry & Biology 17, 449–459, May 28, 2010 ª2010 Elseviernanospray source of a discovery ORBITRAP instrument (Thermo Fischer
Scientific) at a flow rate of 0.5 mL min1. The MS method used a scan range
of 150–1600 m/z and was composed of MS and MS/MS events using both
the Orbitrap as the analyzer (at a resolution of 30,000) to get high precision
on the molecular and on the fragments ions. The CID fragmentation collision
energy used was set to 35 eV, and the MS/MS scan range was set to
100–2000 m/z. QualBrowser from XCalibur was used to read the spectra.
Analyses involving coupling of HPLC to mass spectrometry were performed
with an series 1100 Agilent chromatographic system associated to SCIEX API
3000 triple quadrupolar mass spectrometer. Separation was performed on an
octadecylsilyl ODB Uptisphere column (150 3 2 mm ID, 5 mm particle size,
Montluc¸on, France), using a gradient of acetonitrile in 2 mM ammonium
formate. MS2 spectra were obtained by selecting pseudo-molecular ion in
quadrupole 1 and fragmenting it in the collision cell. The fragmentation spec-
trum was recorded in the 50–520 mass unit range.
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